WO2001038558A3 - Age-corrected mmp-assay for malignant pathologies - Google Patents

Age-corrected mmp-assay for malignant pathologies Download PDF

Info

Publication number
WO2001038558A3
WO2001038558A3 PCT/GB2000/004437 GB0004437W WO0138558A3 WO 2001038558 A3 WO2001038558 A3 WO 2001038558A3 GB 0004437 W GB0004437 W GB 0004437W WO 0138558 A3 WO0138558 A3 WO 0138558A3
Authority
WO
WIPO (PCT)
Prior art keywords
mmp
assay
value
age
corrected
Prior art date
Application number
PCT/GB2000/004437
Other languages
French (fr)
Other versions
WO2001038558A2 (en
Inventor
Michael John Owen Wakelam
Tariq Ismail
Original Assignee
Univ Birmingham
Michael John Owen Wakelam
Tariq Ismail
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Birmingham, Michael John Owen Wakelam, Tariq Ismail filed Critical Univ Birmingham
Priority to AU15318/01A priority Critical patent/AU1531801A/en
Publication of WO2001038558A2 publication Critical patent/WO2001038558A2/en
Publication of WO2001038558A3 publication Critical patent/WO2001038558A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides an assay for the detection of a malignant pathology such as colorectal cancer. The assay comprises the steps of measuring a value for the level of a first matrix metalloproteinase (MMP) in a blood serum sample obtained from a patient, the MMP being one whose level is altered by the malignant pathology, calibrating the value, and comparing the calibrated value with a reference value. Deviation of the calibrated value from the reference value is indicative of the malignant pathology in the patient.
PCT/GB2000/004437 1999-11-22 2000-11-22 Age-corrected mmp-assay for malignant pathologies WO2001038558A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU15318/01A AU1531801A (en) 1999-11-22 2000-11-22 Novel assay

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9927576.0 1999-11-22
GBGB9927576.0A GB9927576D0 (en) 1999-11-23 1999-11-23 Novel assay

Publications (2)

Publication Number Publication Date
WO2001038558A2 WO2001038558A2 (en) 2001-05-31
WO2001038558A3 true WO2001038558A3 (en) 2001-11-08

Family

ID=10864919

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/004437 WO2001038558A2 (en) 1999-11-22 2000-11-22 Age-corrected mmp-assay for malignant pathologies

Country Status (3)

Country Link
AU (1) AU1531801A (en)
GB (1) GB9927576D0 (en)
WO (1) WO2001038558A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6906036B2 (en) 2001-08-16 2005-06-14 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
US7071164B2 (en) 2001-08-16 2006-07-04 Kimberly-Clark Worldwide, Inc. Anti-cancer and wound healing compounds
US7186693B2 (en) 2001-08-16 2007-03-06 Kimberly - Clark Worldwide, Inc. Metalloproteinase inhibitors for wound healing
US7094754B2 (en) 2001-08-16 2006-08-22 Kimberly-Clark Worldwide, Inc. Anti-aging and wound healing compounds
CA2467460A1 (en) 2001-11-19 2003-05-30 Parallele Bioscience, Inc. Multiplex oligonucleotide addition and target amplification
US7148194B2 (en) 2002-12-30 2006-12-12 Kimberly-Clark Worldwide, Inc. Method to increase fibronectin
US7189700B2 (en) 2003-06-20 2007-03-13 Kimberly-Clark Worldwide, Inc. Anti-chrondrosarcoma compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07159402A (en) * 1993-12-09 1995-06-23 Kyodo Nyugyo Kk Iv type collagenase measuring method
WO1997038314A1 (en) * 1996-04-09 1997-10-16 British Biotech Pharmaceuticals Limited Diagnosis and monitoring of neurological disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07159402A (en) * 1993-12-09 1995-06-23 Kyodo Nyugyo Kk Iv type collagenase measuring method
WO1997038314A1 (en) * 1996-04-09 1997-10-16 British Biotech Pharmaceuticals Limited Diagnosis and monitoring of neurological disease

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
FESTUCCIA CLAUDIO ET AL: "Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells.", INTERNATIONAL JOURNAL OF CANCER, vol. 69, no. 5, 1996, pages 386 - 393, XP000997903, ISSN: 0020-7136 *
HURST NICHOLAH G ET AL: "Serological pre-hospital detection of colorectal neoplasia in a symptomatic cohort: The next step towards a population screening programme.", GASTROENTEROLOGY, vol. 118, no. 4 Suppl. 2 Part 1, April 2000 (2000-04-01), 101st Annual Meeting of the American Gastroenterological Association and the Digestive Disease Week.;San Diego, California, USA; May 21-24, 2000, pages SSAT A1029, XP000993029, ISSN: 0016-5085 *
MANICOURT DANIEL-HENRI ET AL: "Serum levels of collagenase, stromelysin-1, and TIMP-1: Age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratan sulfate in patients with osteoarthritis.", ARTHRITIS & RHEUMATISM, vol. 37, no. 12, 1994, pages 1774 - 1783, XP000997889, ISSN: 0004-3591 *
PATENT ABSTRACTS OF JAPAN vol. 1995, no. 09 31 October 1995 (1995-10-31) *
STEARNS MARK E ET AL: "Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: Effects of taxol.", ONCOLOGY RESEARCH, vol. 6, no. 4-5, 1994, pages 195 - 201, XP000997890 *
ZUCKER STANLEY ET AL: "M-r 92000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer.", CANCER RESEARCH, vol. 53, no. 1, 1993, pages 140 - 146, XP000993259, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2001038558A2 (en) 2001-05-31
GB9927576D0 (en) 2000-01-19
AU1531801A (en) 2001-06-04

Similar Documents

Publication Publication Date Title
NO20010011L (en) Optical sensor for in-situ measurement of analytes
Lewis et al. Point-of-care assay platform for quantifying active enzymes to femtomolar levels using measurements of time as the readout
EP1318399A3 (en) Passive sample detection to initiate timing of an assay
Hefnawy et al. Spectrofluorometric determination of alpha-aminocephalosporins in biological fluids and pharmaceutical preparations
AU4694499A (en) Trace level detection of analytes using artificial olfactometry
EP0981048A3 (en) Blood clot detector
EP1225442A3 (en) Method and apparatus for using infrared readings to detect misidentification of a diagnostic test strip in a reflectance spectrometer
EP2131198A3 (en) Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
MXPA02010106A (en) Determination of sample volume adequacy in biosensor devices.
WO2005040396A3 (en) qRT-PCR ASSAY SYSTEM FOR GENE EXPRESSION PROFILING
WO2000013580A8 (en) Device for determination of an analyte in a body fluid intergrated with an insulin pump
AU1725200A (en) Simultaneous determination of equilibrium and kinetic properties
AU1740700A (en) Method and apparatus for performing a lateral flow assay
EP1359417A3 (en) Devices and methods for analyte concentration determination
CA2330629A1 (en) Method and device for predicting physiological values
AU1671300A (en) Cancer detection method and reagents
DK1095273T3 (en) Biodegradable optical sensor for in situ measurement of analytes
WO2003106964A3 (en) High throughput methods and devices for assaying analytes in a fluid sample
WO2001038558A3 (en) Age-corrected mmp-assay for malignant pathologies
Bencivenga et al. Plasmonic optical fiber biosensor development for point-of-care detection of malondialdehyde as a biomarker of oxidative stress
CA2510377A1 (en) Use of nicotinamide n-methyltransferase as a marker for colorectal cancer
WO2003100006A3 (en) Method of improved prostate cancer detection
WO2002033402A3 (en) Establishment of biological cut-off values for predicting resistance to therapy
WO2002016943A3 (en) Differential immunoassay
KR100730900B1 (en) How to improve the accuracy of quasi-quantitative measurements of analytes in body fluid samples

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase